open access
The analysis of the level of Treg lymphocytes in the blood of patients with endometrial cancer before and after the surgery — preliminary study
Affiliations- Department of Oncology and Brachytherapy Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
- Katedra i Klinika Radioterapii, Onkologii i Ginekologii Onkologicznej Collegium Medium UMK w Bydgoszczy
- Centrum Onkologii w Bydgoszczy, Romanowskiej 2, 85-796 Bydgoszcz
- Department of Paediatric Otolaryngology, Chair of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
open access
Abstract
Introduction. The progression of cancer is a complex process involving host-tumour interactions taking place in cancer and in the cancer microenvironment. The tumour remodels the microenvironment into the suppressive profile by various mechanisms. One of the most important elements of this mechanism is the inducing of the infiltration of Treg lymphocytes into cancer and its microenvironment. The aim of the present study was to evaluate the alterations of the Treg cell population in the peripheral blood of patients before and after the surgical treatment for endometrial cancer.
Material and methods. For the present study 24 patients with endometrial cancer were recruited. All the patients were treated surgically. The peripheral blood samples were collected from the endometrial cancer patients before operation and three days after the surgical procedure and evaluated using flow cytometry method.
Results. CD25+ CD4+ FOXP3+ T cells were found in all the examined peripheral blood samples derived from the endometrial cancer patients in the days before and following applied surgery. We observed differences before and after the applied surgical procedure in patients treated for uterine cancer. The highest number of Treg cells in the peripheral blood was demonstrated before the surgical procedure; it diminished statistically significantly following the surgery.
Conclusions. The decrease of the percentage of Treg cells in blood sera in patients following radical surgical treatment might be useful in measuring the radicalism of the treatment. The monitoring of the level of selective immune system suppression related to Treg cell blood serum levels during cancer therapy might support a decision to supplement the standard therapy with immunotherapy or to increase the degree of radicalism of the applied therapy.
Abstract
Introduction. The progression of cancer is a complex process involving host-tumour interactions taking place in cancer and in the cancer microenvironment. The tumour remodels the microenvironment into the suppressive profile by various mechanisms. One of the most important elements of this mechanism is the inducing of the infiltration of Treg lymphocytes into cancer and its microenvironment. The aim of the present study was to evaluate the alterations of the Treg cell population in the peripheral blood of patients before and after the surgical treatment for endometrial cancer.
Material and methods. For the present study 24 patients with endometrial cancer were recruited. All the patients were treated surgically. The peripheral blood samples were collected from the endometrial cancer patients before operation and three days after the surgical procedure and evaluated using flow cytometry method.
Results. CD25+ CD4+ FOXP3+ T cells were found in all the examined peripheral blood samples derived from the endometrial cancer patients in the days before and following applied surgery. We observed differences before and after the applied surgical procedure in patients treated for uterine cancer. The highest number of Treg cells in the peripheral blood was demonstrated before the surgical procedure; it diminished statistically significantly following the surgery.
Conclusions. The decrease of the percentage of Treg cells in blood sera in patients following radical surgical treatment might be useful in measuring the radicalism of the treatment. The monitoring of the level of selective immune system suppression related to Treg cell blood serum levels during cancer therapy might support a decision to supplement the standard therapy with immunotherapy or to increase the degree of radicalism of the applied therapy.
Keywords
Treg lymphocytes, endometrial cancer
About this articleTitle
The analysis of the level of Treg lymphocytes in the blood of patients with endometrial cancer before and after the surgery — preliminary study
Journal
Issue
Article type
Original article
Pages
97-101
Published online
2018-01-31
Page views
877
Article views/downloads
749
DOI
Bibliographic record
Medical Research Journal 2017;2(3):97-101.
Keywords
Treg lymphocytes
endometrial cancer
Authors
Marta Biedka
Tamara Kuźba-Kryszak
Łukasz Wicherek
Magdalena Dutsch-Wicherek
References (29)- Leffers N, Gooden MJM, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009; 58(3): 449–459.
- Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51): 18538–18543.
- Zhang YL, Li J, Mo HY, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer. 2010; 9: 4.
- Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9): 942–949.
- Barnett B, Kryczek I, Cheng P, et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005; 54(6): 369–377.
- Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002; 2(6): 389–400.
- Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T Cells and Immune Tolerance. Cell. 2008; 133(5): 775–787.
- Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006; 212: 8–27.
- Hamidinia M, Ghafourian Boroujerdnia M, Talaiezadeh A, et al. Increased P-35, EBI3 transcripts and other Treg markers in peripheral blood mononuclear cells of breast cancer patients with dfferent clinical stages. Adv Pharm Bull. 2015; 5(2): 261–267.
- Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007; 445(7129): 771–775.
- Hori S, Nomura T, Sakaguchi S, et al. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609): 1057–1061.
- Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005; 6(11): 1142–1151.
- Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450(7169): 566–569.
- Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012; 22(4): 327–334.
- Whiteside TL. Clinical impact of regulatory T cells (Treg) in cancer and HIV. Cancer Microenviron. 2015; 8(3): 201–207.
- Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107(12): 2866–2872.
- Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34): 5373–5380.
- Feng LL, Wang X. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J (Engl). 2010; 123(22): 3334–3342.
- Nakamura T, Shima T, Saeki Ai, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007; 98(6): 874–881.
- Zeng C, Yao Y, Jie W, et al. Up-regulation of Foxp3 participates in progression of cervical cancer. Cancer Immunol Immunother. 2013; 62(3): 481–487.
- Zhang Y, Ma D, Zhang Y, et al. The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin Chim Acta. 2011; 412(11-12): 894–900.
- Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007; 56(11): 1743–1753.
- Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006; 177(10): 7398–7405.
- Whiteside TL, Mandapathil M, Szczepanski M, et al. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer. 2011; 98(2): E25–E31.
- Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol. 2000; 164(4): 2214–2220.
- Cole WH, Humphrey L. Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg. 1985; 202(1): 9–20.
- Wicherek L, Jozwicki W, Windorbska W, et al. Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am J Reprod Immunol. 2011; 66(5): 444–450.
- Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3): 203–213.
- Zhang P, Côté AL, de Vries VC, et al. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 2007; 67(13): 6468–6476.